Moderna: The Software of Life - [Business Breakdowns, EP. 13]

Moderna: The Software of Life – Decoding

At a Glance

Guests: Jason Kelly (CEO of Ginkgo Bioworks, providing a foundational perspective on the biotech industry) and Matthew Harrison (Morgan Stanley biotech analyst, offering an investment analysis perspective). The core thesis of this episode: Moderna's mRNA platform is essentially the "software of life"—a programmable cell programming technology, with the COVID-19 vaccine serving only as the first large-scale validation of its capabilities. The most impactful judgment of the entire episode comes from Jason Kelly: "Moderna's COVID vaccine success for nucleic acid drugs is equivalent to what insulin was for protein drugs in 1978—this marks the starting point of an entirely new drug category."

---

1. The Essence of mRNA: From "Chemical Drugs" to "Software Drugs"

Jason Kelly believes that Moderna represents not a continuation of traditional pharmaceutical companies, but a fundamental shift in the drug development paradigm.

• Historical Context: Drug development has gone through three eras — ① Small molecule chemical drugs (e.g., Pfizer's traditional drugs); ② Protein drugs (Genentech's insulin, the first gene cut-and-paste in 1978); ③ Nucleic acid drugs (Moderna's mRNA, writing code directly into cells).
• Mechanism Breakdown: DNA is the cell's "hard drive" (permanent storage), while mRNA is the "code being executed" (temporary instructions). Moderna's approach is to encapsulate mRNA encoding a specific protein in lipid nanoparticles and inject it into the body. The cell "reads" this code and automatically produces the target protein — in the COVID vaccine scenario, this means producing a fragment of the viral spike protein to activate the immune system.
• Key Analogy: Kelly emphasizes that this is like "installing a temporary software patch on a computer" — "mRNA is the code your cells are currently executing. What Moderna does is pop in and say, here's a piece of RNA, run it. Your cells will obediently run it because that's what they do when they see RNA."

Matthew Harrison adds on the technical barriers: Moderna has solved two core issues — ① Delivery system (lipid nanoparticles, protecting mRNA as it enters cells); ② Immune evasion (using chemical modifications to prevent mRNA from being cleared by the human immune system as a foreign substance). These two technologies are the infrastructure of the platform, not the R&D outcome of a single drug.

---

2. Platform vs. Single Drug: Moderna’s Differentiated Capital Structure

Harrison points out that Moderna was designed from the outset as a "platform company" rather than a "single-drug company," which determines its capital strategy and pipeline scale.

• Capital Structure Differences: Typical biotech startups raise only a few million dollars in Series A funding, focusing on a single drug candidate. Moderna’s early funding rounds were far larger than its peers, as its goal was an "industrialized platform" rather than "advancing a single asset."
• Pipeline Scale Comparison: Moderna has approximately 15 clinical candidates, whereas biotech companies of a similar age (about 10 years) typically have only 2-3. Harrison emphasizes: "This is a multiple-fold gap."
• Evolution of Collaboration Model: In the early stages, Moderna secured upfront payments (approximately $300 million) and milestone payments (industry term "BioBucks") through partnerships with large pharma companies like AstraZeneca and Alexion, while retaining full rights to other platform areas. The COVID-19 vaccine was Moderna’s first wholly owned product—"Once you reach critical scale, you no longer need partnerships. You can fund clinical trials yourself and own 100% of the upside."

Jason Kelly adds the positive feedback effect of the platform economy: "Every success Moderna achieves in the therapeutic field drives advances in the underlying DNA printing and cell programming technology—which in turn makes the vegan cheese a year later even better. They are great applications that drive improvements in the operating system."

---

3. Risk Stratification in Drug Development: Technical Risk vs. Biological Risk

Harrison proposes a key analytical framework—drug development risks should be divided into two categories, and the mRNA platform primarily alters one of them.

• Technical Risk: Whether the drug works as designed—whether delivery is successful and whether the intended molecule is produced. Harrison argues that once the mRNA platform is validated for a specific indication, the technical risk for subsequent drugs should be "very low," because "the only thing that changes is the sequence inside the mRNA; the delivery method and drug properties remain identical."
• Biological Risk: Even if the drug works as designed, whether the target molecule can actually treat the disease. This depends on the understanding of disease biology and is independent of the platform. Harrison warns: "Biological risk may still be high. Until you put the drug into a clinical trial and see if it does what you hope it will do—it might not."
• Iteration Speed Advantage: In traditional drug development, only 1-2 candidate molecules can typically be tested in the same time frame; the mRNA platform can test 100 different sequences simultaneously. "Your ability to iterate and identify the best construct is completely different."

Data Support: The COVID vaccine went from obtaining the viral sequence to designing a candidate vaccine in just days, and to obtaining the first batch of animal test formulations in just weeks—Harrison notes that "this is typically a multi-year process."

---

4. Valuation Framework and Key Variables

Harrison outlines the valuation logic for biotech companies and highlights Moderna's unique characteristics.

• Standard Valuation Method: For each drug candidate, assess its commercial opportunity (market size) × probability of success (based on factors such as clinical data stage, platform maturity, management, etc.), discount, and sum up. Differences in investors' assessments of success probabilities are the primary source of valuation divergence.
• Moderna's Uniqueness: Harrison emphasizes that investors should not include all pipeline projects in the valuation — "Some investors only focus on the most advanced projects because those are the stock catalysts." For Moderna, the key observation point is whether it can validate another vertical beyond vaccines (e.g., rare diseases).
• Financial Data:
• The cost of goods sold ratio for the COVID vaccine is approximately 20% (comparable to other vaccines; chemical tablets are 5-10%, biologics are 17-22%).
• The operating profit margin is approximately 50% (traditional pharmaceutical companies are 35-40%, specialized biotech firms are 45-52%).
• In 2021, announced advance purchase agreements exceeded 800 million doses, with U.S. pricing at $15-16.50/dose, totaling approximately $18 billion in revenue (the vast majority recognized in 2021).

---

5. Conditions and Risks of Becoming the "Next Pfizer"

Harrison outlines the core variables for Moderna's long-term success.

• What must be done right:

1. Reinvest the capital from COVID vaccines (approximately $18 billion in revenue) into the platform — "You have proven the vaccine platform works; now the question is: what other vaccine opportunities can you capture with this validated platform?" (e.g., flu, CMV)

2. Establish proof of concept in other verticals (e.g., rare diseases), then "go all in" — "Once you de-risk a vertical, commit fully."

• Potential pitfalls:

1. Inherent risk of drug development failure — "Drugs can fail for reasons we don't fully understand. This risk remains, as most other programs are still in development."

2. Technology competition — Other mRNA companies may catch up, or other technology platforms (e.g., AAV gene therapy, protein replacement therapy) may prove superior to mRNA in specific areas. Harrison likens this to the "Blu-ray vs. HD DVD" format war.

• Falsification signal: If Moderna fails to establish proof of concept in its next vertical beyond vaccines (e.g., rare diseases) — i.e., cannot demonstrate that mRNA can be safely administered multiple times and produce sufficient protein levels — the market will reassess its platform value.

---

6. The Broader Picture of Synthetic Biology

Jason Kelly places Moderna within the larger context of the synthetic biology revolution, arguing its impact extends far beyond medicine.

• The essence of programmable cells: "Computers are universal machines—streaming video today, running electronic medical records tomorrow—but they only move information. The magic of cells is that they move atoms."
• Industries to be disrupted: Food (the hemoglobin in the Impossible Burger comes from engineered yeast), materials (animal-free leather), environmental remediation (degrading hard-to-treat pollutants like PFAS), construction materials—"every physical goods industry is ultimately a biotech industry; they just haven't realized it yet."
• Analogy to the platform economy: "Moderna is a great application that drives improvements in the underlying operating system—just as Facebook developed the Cassandra database, which every company now uses. Horizontal platform companies (like Ginkgo) benefit from these applications and then, in turn, enable new applications in other markets."

---

Mentioned Positions

Position	Analyst Stance	Key Data
Moderna	Bullish (leading platform technology, successful COVID vaccine validation)	Pipeline of approximately 15 drug candidates; vaccine cost of sales ratio 20%, operating margin 50%; 2021 advance purchase agreements of approximately $18 billion
BioNTech	Neutral (similar technology but requires partnership with Pfizer)	50:50 profit split with Pfizer
Pfizer	Neutral (mentioned as BioNTech's partner)	No specific data provided
Genentech	Historical reference (benchmark in the protein drug era)	Started with insulin, grew into a multi-billion-dollar company
Ginkgo Bioworks	The analyst's own company, referenced as a platform company	Monthly production capacity of 50 million base pairs of DNA (compared to 50,000 base pairs over 5 years during the analyst's PhD)
Impossible Foods	Case study of synthetic biology in the food sector	Uses engineered yeast to produce hemoglobin (heme)

---

Judgments Worth Remembering

1. Jason Kelly: "Moderna's success with the COVID vaccine for nucleic acid drugs is equivalent to what insulin in 1978 was for protein drugs—this is the starting point of an entirely new drug category." Support: The 95% effective mRNA vaccine marks the first large-scale human validation of nucleic acid drugs, unlocking possibilities ranging from vaccines to cancer treatments to rare diseases.

2. Matthew Harrison: "Moderna was designed from the outset as a platform company, not a single-drug company—they knew that if they succeeded, it wouldn't be through one drug, but through hundreds." Support: Early funding rounds far exceeded those of peers, and the pipeline size (approximately 15 clinical candidates) is 5–7 times that of companies of the same age.

3. Jason Kelly's "Three Eras of Synthetic Biology" framework: Chemical drugs → Protein drugs (cut and paste) → Nucleic acid drugs (write code). Support: Each era corresponds to a different drug development paradigm, and Moderna represents the beginning of the third era.

4. Matthew Harrison's "Risk Dichotomy": Technical risk vs. biological risk. Support: The mRNA platform primarily reduces technical risk (delivery, expression), but biological risk (whether the target molecule can actually treat the disease) persists and is unpredictable—"until you put the drug into a clinical trial and see if it does what you hope it will do."

5. Jason Kelly: "Computers only move information; cells move atoms. Synthetic biology will disrupt all physical goods industries—food, medicine, building materials, electronics—they are all biotech industries that just haven't realized it yet." Support: The Impossible Burger (food), animal-free leather (materials), and PFAS degradation (environmental remediation) are already real-world examples.

6. Matthew Harrison's valuation principle: "Investors should not include all pipeline projects in their valuations—differences in investors' judgments of success probabilities are the main source of valuation divergence." Support: Biotech company valuation = commercial opportunity per drug × probability of success, where the probability assessment depends on subjective evaluations of platform maturity, clinical data, management, and other factors.

7. Jason Kelly's "Platform Positive Feedback" analogy: "Moderna is a great application that drives improvements in the underlying operating system—just as Facebook developed the Cassandra database, which every company now uses." Support: Each success in the therapeutic field drives the scaling and cost reduction of DNA printing and cell programming technologies, in turn enabling applications in food, materials, and other sectors.

8. Matthew Harrison's condition for Moderna to become "the next Pfizer": "Validate another vertical beyond vaccines—if they establish proof of concept in rare diseases, the market will see the iterative capability and then fully commit." Support: The key falsification signal is whether mRNA can be proven to be safely administered multiple times and produce sufficient levels of protein.